Sitemap

Oxford Covid Vaccine Works In All Ages, Trials Suggest

More...

Diego Maradona: Argentina Legend Dies Aged 60

Football legend Diego Maradona, one of the...

Serbian Student Heads Second-Placed Team At Internet Innovation Competition

Mensa Serbia said on Tuesday that a...

EIB Supports Digitalisation Of Schools With €65 Million

Modern IT equipment and high-speed internet...

News

EBRD, EU And WBIF Financing Construction Of “Peace Highway” In Serbia

EBRD loan of up to €85 million to finance Niš-Pločnik section of “Peace Highway” “Peace Highway” is a...

Diego Maradona: Argentina Legend Dies Aged 60

Football legend Diego Maradona, one of the greatest players of all time, has died at the age of 60. The...

Serbian Student Heads Second-Placed Team At Internet Innovation Competition

Mensa Serbia said on Tuesday that a Serbian doctoral candidate headed the team that won silver at the China...

EIB Supports Digitalisation Of Schools With €65 Million

Modern IT equipment and high-speed internet for primary and secondary schools across Serbia. 50 000 teachers to improve...

G20 Summit: G20 Leaders United To Address Major Global Pandemic And Economic Challenges

President of the European Commission, Ursula von der Leyen, and President of the European Council, Charles Michel, represented the EU at...

Covid vaccine being trialled by Oxford University and AstraZeneca offers hope for all age groups

One of the world’s leading Covid-19 experimental vaccines produces an immune response in older adults as well as the young, its developers say, raising hopes of protection for those most vulnerable to the coronavirus that has caused social and economic chaos around the world.

Neither Oxford University nor its commercial partner AstraZeneca would release the data from the early trials showing the positive effects, which are being submitted to a peer-reviewed journal. But AstraZeneca confirmed the basic findings about the vaccine it calls AZD1222, which were shared at a closed academic meeting.

The phase 2 trials have shown that people over the age of 56 – and some over 70 – produced the same sort of antibody response as younger volunteers. Whether older people would be protected has always been a key question for the vaccines being developed. The body’s natural immune system and therefore its ability to fight any virus weakens with age, which is why the Covid death rate rises in older people.

The data also shows that fewer side-effects – referred to by the scientists as “reactogenicity” – were reported in the older volunteers, which is encouraging, although it could mean fewer of them reported issues such as a sore arm.

“It is encouraging to see immunogenicity responses were similar between older and younger adults and that reactogenicity was lower in older adults, where the Covid-19 disease severity is higher. The results further build the body of evidence for the safety and immunogenicity of AZD1222,” said an AstraZeneca spokesman.

A vaccine that works is seen as a game-changer in the battle against coronavirus, which has killed more than 1.15 million people, shuttered swathes of the global economy and turned normal life upside down for billions of people. However, few think the first vaccines will be fully protective. They may instead reduce the severity of illness, so that people avoid hospital and deaths are reduced. They may also not last, so that boosters will be needed.

The data also shows that fewer side-effects – referred to by the scientists as “reactogenicity” – were reported in the older volunteers, which is encouraging, although it could mean fewer of them reported issues such as a sore arm.

“It is encouraging to see immunogenicity responses were similar between older and younger adults and that reactogenicity was lower in older adults, where the Covid-19 disease severity is higher. The results further build the body of evidence for the safety and immunogenicity of AZD1222,” said an AstraZeneca spokesman.

A vaccine that works is seen as a game-changer in the battle against coronavirus, which has killed more than 1.15 million people, shuttered swathes of the global economy and turned normal life upside down for billions of people. However, few think the first vaccines will be fully protective. They may instead reduce the severity of illness, so that people avoid hospital and deaths are reduced. They may also not last, so that boosters will be needed.

However, most experts outside the company, and the UK health secretary, Matt Hancock, expect it not to be available until 2021. Asked if some people could receive a vaccine this year, Hancock told the BBC: “I don’t rule that out but that is not my central expectation.”

Related

Russia

Testing Coronavirus Vaccine Prototypes on Animals

Russian scientists have begun testing prototypes of potential vaccines against the coronavirus on animals in a laboratory in Siberia, it was said in a...

Ksenija Purković, Country Director at AstraZeneca, Serbia

Health Sector According to The Nordic Recipe

Apart from the financial aspect, AstraZeneca can contribute greatly to developing or implementing procedures and processes in the healthcare sector with best practices shared...

Advertisement

Hancock said a vaccine was not yet ready but he was preparing logistics for a possible rollout, mostly in the first half of 2021. AstraZeneca has committed to mass manufacturing and has a capacity of 3bn doses – which equates to enough for 1.5 billion people globally getting the two-dose vaccine. It has also signed deals with manufacturers in other countries, such as India.

The final trials (phase 3), looking to see a significant difference in the numbers of deaths between those vaccinated and those who are not, are taking place in six countries. Trials in the US, which were paused after a volunteer in the UK became ill, have resumed. The other countries participating are South Africa, Brazil, Japan and India.

The vaccine is expected to be one of the first from big pharma to secure regulatory approval, along with one from Pfizer and BioNTech.

Work began on the Oxford vaccine in January. Called AZD1222 or ChAdOx1 nCoV-19, the viral-vector vaccine is made from a weakened version of a common cold virus that causes infections in chimpanzees.

Stephen Evans, a professor of pharmacoepidemiology at the London School of Hygiene & Tropical Medicine, cautioned that no conclusions about the efficacy of the vaccine should be drawn until the data had been published.

“In order to comment properly on this we need to see the data,” he said. “It is encouraging that the investigators suggest that the immune responses measured in the blood seem to show efficacy both above, as well as below, age 70. The later phase trials are needed to see if the immune responses translate into clinical efficacy in preventing infection. These will involve much larger numbers and it is wise to not be too optimistic until those trials have completed.” Raised antibody levels in the blood indicated but did not guarantee protection from the virus multiplying in the body, he said.

Source: theguardian.com

Related Articles

Government Passes New Anti-coronavirus Measures

The Serbian government adopted new measures to suppress the epidemic caused by the COVID-19 infectious disease, whose implementation will begin on 24 November 2020. The...

US pharma firm Moderna says its COVID-19 vaccine is 94.5% effective

Moderna said that Phase 3 stage analysis suggested its coronavirus vaccine could prevent COVID-19. The news comes a week after Pfizer and German drug-maker...

Coronavirus Vaccine: EU Seals Deal With BioNTech, Pfizer

The EU has greenlit a deal with the US and German firms to secure 300 million doses of their coronavirus vaccine for the bloc....

Coronavirus Digest: Europe Tightens Restrictions To Control Spread Of COVID-19

The Netherlands is going into a partial lockdown for at least four weeks. Meanwhile, Italy has imposed new restrictions on public gatherings, restaurants, sports...

Japan To Donate A Total Of 100 Million Yen To Serbia For COVID Fight

The Government of Japan will provide a total amount of 100 million yen (about 820,000 euros) to the Government of Serbia with the aim...

Italy Sends Serbia The Medical Team To Help Fight COVID19

The Italian Embassy in Belgrade announces that a six-member medical team has arrived in Serbia: two anesthesiologists, one emergency doctor, one specialist in infectious...

EU Supports Serbia’s Fight Against Coronavirus By Hiring 200 Medical Professionals

Doctor, nurses, administrative staff—some 200 medical professionals will be given employment as part of the European Union’s assistance in fighting coronavirus in Serbia. Head of...

59 New Cases Of Coronavirus Confirmed

The Ministry of Health announced today that samples of 5,470 people have been tested for coronavirus since the last report, of which 59 are...